Transformation induced by Ewing's sarcoma associated EWS/FLI-I is suppressed by KRAB/FLI-I

被引:11
作者
Chan, D [1 ]
Wilson, TJ [1 ]
Xu, D [1 ]
Cowdery, HE [1 ]
Sanij, E [1 ]
Hertzog, PJ [1 ]
Kola, I [1 ]
机构
[1] Monash Univ, Monash Inst Reprod & Dev, Ctr Funct Genom & Human Dis, Melbourne, Vic 3004, Australia
关键词
Ewing's sarcoma; repressor; EWS; KRAB; Fli-I;
D O I
10.1038/sj.bjc.6600669
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ewing's sarcoma is a childhood bone tumour with poor prognosis, most commonly associated with a t(11;22)(q24;q12) reciprocal translocation that fuses the EWS and FLI-1 genes, resulting in the production of an aberrant chimeric transcription factor EWS/FLI-1. To elucidate the mechanisms by which EWS/FLI-1 mediates transformation in mouse models, we have generated a murine Ews/Fli-1 fusion protein. We demonstrate that this protein transforms fibroblast cells in vitro similar to human EWS/FLI-1 as demonstrated by serum and anchorage-independent growth, the formation of tumours in nude mice and elevation of the oncogenic marker c-myc. Furthermore, transformation of these cells was inhibited by a specific repressor, KRAB/FLI-1. The KRAB/FLI-1 repressor also suppressed the tumorigenic phenotype of a human Ewing's sarcoma cell line. These findings suggest that the transformed phenotype of Ewing's sarcoma cells can be reversed by using the sequence-specific FLI-1-DNA-binding domain to target a gene repressor domain. The inhibition of EWS/FLI-1 is the first demonstration of the KRAB domain suppressing the action of an ETS factor. This approach provides potential avenues for the elucidation of the biological mechanisms of EWS/FLI-1 oncogenesis and the development of novel therapeutic strategies. (C) 2003 Cancer Research UK.
引用
收藏
页码:137 / 145
页数:9
相关论文
共 49 条
[1]  
AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO
[2]  
2-U
[3]   EWS/FLI1 up regulates mE2-C, a cyclin-selective ubiquitin conjugating enzyme involved in cyclin B destruction [J].
Arvand, A ;
Bastians, H ;
Welford, SM ;
Thompson, AD ;
Ruderman, JV ;
Denny, CT .
ONCOGENE, 1998, 17 (16) :2039-2045
[4]  
Ayyanathan K, 2000, CANCER RES, V60, P5803
[5]   DNA-BINDING AND TRANSCRIPTIONAL ACTIVATION PROPERTIES OF THE EWS-FLI-1 FUSION PROTEIN RESULTING FROM THE T(1122) TRANSLOCATION IN EWING SARCOMA [J].
BAILLY, RA ;
BOSSELUT, R ;
ZUCMAN, J ;
CORMIER, F ;
DELATTRE, O ;
ROUSSEL, M ;
THOMAS, G ;
GHYSDAEL, J .
MOLECULAR AND CELLULAR BIOLOGY, 1994, 14 (05) :3230-3241
[6]   Toward controlling gene expression at will:: Specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks [J].
Beerli, RR ;
Segal, DJ ;
Dreier, B ;
Barbas, CF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (25) :14628-14633
[7]   THE EVOLUTIONARILY CONSERVED KRUPPEL-ASSOCIATED BOX DOMAIN DEFINES A SUBFAMILY OF EUKARYOTIC MULTIFINGERED PROTEINS [J].
BELLEFROID, EJ ;
PONCELET, DA ;
LECOCQ, PJ ;
REVELANT, O ;
MARTIAL, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (09) :3608-3612
[8]  
BRAUN BS, 1995, MOL CELL BIOL, V15, P4623
[9]   Theme editors' introduction: Advancing interactive visualization and computational steering [J].
Chen, JX ;
Rine, D ;
Simon, HD .
IEEE COMPUTATIONAL SCIENCE & ENGINEERING, 1996, 3 (04) :13-17
[10]   The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: The effect of the ligands on molecular targets involved in proliferation [J].
Darnell, G ;
Richardson, DR .
BLOOD, 1999, 94 (02) :781-792